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(57) ABSTRACT 
The invention relates to the construction of protease 
deficient Escherichia coli hosts which when combined 
with an expression system are useful for the production 
of proteolytically sensitive polypeptides. The invention 
also includes examples of particular mutant Escherichia 
coli deficient in up to four proteases. 
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PROTEASE-DEFICIENT BACTERIAL STRANS 
FOR PRODUCTION OF PROTEOLYTICALLY 
SENSITIVE POLYPEPTOES 
The United States Government may have certain 
rights in the present invention pursuant to the terms of 
Grant No. CBT-8657471 awarded by the National Sci 
ence Foundation. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The invention relates to the construction of protease 
deficient bacteria, particularly E. coli, using methods of 
recombinant DNA technology, and to the expression of 
polypeptides by the protease-deficient cells. In a partic 
ular aspect of the invention, improved yields of protease 
sensitive polypeptide products are accumulated when a 
multiply protease-deficient E. coli is used to generate 
proteolytically sensitive proteins. 
2. Description of Related Art 
Escherichia coli has been the most widely used micro 
organism for the production of commercially important 
recombinant proteins. Despite the lack of certain kinds 
of post-translational processing and the production of 
endotoxins, E. coli presents numerous advantages for 
protein expression. Its genetics are well understood, it 
can be grown to high densities on inexpensive sub 
strates, and fermentation scale-up is straightforward (1). 
A number of useful eukaryotic proteins have been 
cloned and expressed in E. coli including human insulin 
and proinsulin, human and bovine somatotropins, inter 
ferons and tissue plasminogen activator. Recently, Huse 
and coworkers (2) constructed a bacteriophage lambda 
system which allows the expression and rapid screening 
of mouse Fab antibody fragments in E. coli. For most 
biotechnology applications it is advantageous to secrete 
the protein from the cytoplasm. Secretion of the poly 
peptide product can facilitate correct folding, reduce 
protein degradation and simplify subsequent purifica 
tion steps. 
One of the major problems associated with the ex 
pression of heterologous polypeptides in Escherichia coli 
is the degradation of cloned gene products by host 
specific proteases (3). It has been shown that, as in eu 
karyotic cells, energy-dependent processes are impor 
tant for the degradation of E. coli proteins with abnor 
mal conformations (4,5). However, most E. coli pro 
teases hydrolyze peptide bonds via an energy-independ 
ent pathway. At least 25 proteases and peptidases have 
been identified in different cellular compartments of E. 
coli (6,7). The biochemical characterization of these 
enzymes is incomplete and there is relatively little infor 
mation on their physiological role. One or more of these 
proteases may act upon any given polypeptide to effect 
degradation and thereby reduce yields, sometimes quite 
drastically. 
One approach to solving the problem of low polypep 
tide production in bacterial host cells has been the use of 
an inducible expression system in combination with a 
constitutively protease-deficient bacterial host strain. 
This method will operate to increase polypeptide yields 
only if the deficient protease has as its substrate the 
target polypeptide which is being expressed. For exam 
ple, the production of an immunologically functional 
antibody fragment in a constitutively lon and/or 






though such strains have been shown to have a general 
defect in protein degradation. 
Several strains of E. coli deficient in proteases or 
genes controlling the regulation of proteases are known 
(9-11). Some of these strains have been used in attempts 
to efficiently produce proteolytically sensitive polypep 
tides, particularly those of potential medical or other 
commercial interest. 
Some singly protease-deficient mutants of Escherichia 
coli have been prepared. These include a degP deficient 
genetically engineered strain and a spontaneous mutant, 
UT4400, in which the entire ompT gene together with 
a sizable piece of adjacent DNA have been deleted from 
the chromosome (12). Mutants carrying large deletions 
in the Protease III (ptr) gene including adjacent genes 
recC, reces and recd, have been isolated (10). However, 
since the adjacent genes are important for cell viability 
and stable propagation of plasmids in Escherichia coli, 
the mutant strains exhibit growth defects and low pro 
tein production. A Protease III mutant strain has also 









Using a similar rationale, but a genetic engineering 
approach, a method of mutagenizing Escherichia coli to 
produce a cell with a defective periplasmic protease has 
been described (9). A degP deletion mutant was con 
structed and recombined into an E. coli chromosome 
(14). Some workers have shown that the proteolytically 
sensitive fusion protein, protein A-3-lactamase, is stabi 
lized three-fold in such a deg mutant (15,16). 
Most proteins are degraded by more than one prote 
ase. Therefore, the use of mutants deficient in the syn 
thesis of a single enzyme can only partially prevent the 
degradation of the product. Inactivation of multiple 
proteolytic enzymes may lead to higher production. 
The challenge is complex, however, because there is no 
assurance that disablement or deletion of any given 
protease or combination of proteases will result in a 
viable or unchanged host cell or that such manipulation 
will avoid the precipitation of toxic events within the 
cell. 
The genetically engineered protease-deficient micro 
organisms of the present invention have shown unex 
pectedly improved yields of proteolytically sensitive 
polypeptide products while maintaining good growth 
and cell viability. For the first time, a microorganism 
deficient in Protease III has been engineered which, 
unlike mutants previously isolated, is not defective in 
the gene product of adjacent genes recC, recib or recD. 
In addition, three doubly protease defective microor 
ganisms and a triply defective microorganism have been 
engineered. The use of these microorganisms grown 
under optimized conditions significantly broadens the 
potential to produce commercially valuable polypep 
tides. 
SUMMARY OF THE INVENTION 
The present invention relates generally to mutant 
protease-deficient gram-negative bacteria, preferably 
Escherichia coli, that are capable of significantly enhanc 
ing production of proteolytically sensitive polypeptides 
when transformed with appropriate expression vectors. 
In particular, multiply protease-deficient bacterial 
strains have been constructed. These strains are viable 
and show good growth characteristics. They are useful 
in processes for the production of a wide range of 




In general, mutant organisms are constructed from 
strains of unicellular organisms, preferably gram-nega 
tive organisms, for example Salmonella typhimuriu, Er 
wina carotavora and Klebsiella pneumoniae. Most prefer 
able is Escherichia coli. These strains will preferably be 
capable of encoding at least two secreted proteases 
from at least two genes. The mutants constructed from 
these strains will be suitable hosts for transformation 
with a variety of expression vectors resulting in the 
production of various proteins. The proteins produced 
are not native to the mutant host; that is, these proteins 
are heterologous. The mutants are characterized in that 
many of the proteins that can be produced by virtue of 
the expression systems present in the cell will not be 
degraded because of deficiencies in at least two of the 
genes that normally produce proteolytic enzymes. 
In a particular aspect of the invention the mutant 
organism has a deficiency in proteases OmpT, DegP 
and Protease III. Deficiency in each of these proteases 
is caused by a mutation in the respective genes coding 
for these proteases. These genes are omPT, degP and 
ptr. The mutations may be deletions or engineered mu 
tations such as a cut in the gene may be produced and 
the gene subsequently reinserted into the bacterial ge 
nome. In one embodiment of the present invention the 
triply protease-deficient mutant microorganism was 
constructed by transferring a ptr mutation from a mu 
tated strain into another mutant organism having ompT 
and degP deletions. As an example meant only to illus 
trate and not to limit, ompT and/or degP deletion mu 
tants may be selected by standard procedures. For ex 
ample, mutant strain UT4400 is a spontaneous mutant in 
which the entire ompT gene together with a sizable 
piece of adjacent DNA has been deleted from the chro 
mosome. P1 transduction may be used to transfer chro 
mosomal DNA from an ompT mutant into a degP mu 
tant such as KS474. A triply protease-deficient mutant 
strain may then be constructed by generalized P1 trans 
duction transfer of the ptr gene mutation from an appro 
priate strain into double ompT degP mutants. 
It is to be understood that ptr degPompT mutants 
may also be constructed by transferring a ptr mutation. 
into any genetic background deficient in DegP and 
OmpT proteolytic activities by using P1 transduction or 
similar techniques. Alternatively, such mutants may be 
constructed by transferring an ompT mutation into any 
genetic background deficient in Protease III and DegP 
or by transferring a degP mutation in any genetic back 
ground deficient in Protease III and OmpT by using Pl 
transduction or similar techniques. A particular embodi 
ment of this mutant organism is the E. coli stain SF120 
having ATCC Accession No. 55099 which was depos 
ited on Oct. 10, 1990. The OmpT DegP and Protease III 
deficiencies characteristic of the mutant organisms that 
are triply protease-deficient may be characterized in 
different ways depending on the nature of the mutation 
in the respective genes which code for these proteases. 
For example, the mutations in the genes coding for 
these proteases may be due to deletions and such dele 
tions result in no product of the proteins that exhibit the 
proteolytic activity ascribed to DegP, OmpT and Pro 
tease III. However, not all mutations are deletions and 
similar results can be obtained with other mutations 
including point, missense, nonsense and frameshift mu 
tations, mutations resulting from ultraviolet or chemical 
or any general mutagenesis technique, or a combination 
thereof. In certain cases, mutations in portions of the 











product is expressed but there is a substantial loss or 
even lack of proteolytic activity. Mutations in any one 
or more of the three genes may also result in either lack 
of gene product or products having substantially low 
ered activity. 
In another aspect of this invention a mutant organism 
derived from a stain of unicellular organism capable of 
encoding Protease III has been prepared. This mutant is 
characterized as expressing a polypeptide product of 
genes recB, recCand recd while at the same time ex 
hibiting a deficiency in the ptr gene product Protease 
III. Proteolytically sensitive proteins that may be pro 
duced by this mutant organism are not degraded be 
cause of the deficiency in Protease III or if they are 
degraded it is to a very small extent. The polypeptide 
product expressed by genes reces, recCand recd exhib 
its exonuclease V activity. The expression of this activ 
ity appears to be important for the viability of the or 
ganism and the stable propagation of expression vec 
tors. Other ptr mutants reported appear to contain mu 
tations involving deletions of the ptr gene as well as 
genes reces, recC and recD and hence, lack exonuclease 
V activity (10). The result of this appears to be a mutant 
microorganism that has poor growth characteristics and 
exhibits genetic instability. In contrast, the engineered 
mutant constructed as part of this invention exhibits 
normal exonuclease V activity although it lacks Prote 
ase III activity. 
The degPompT mutant organism is deficient in pro 
teases DegP and OmpT due to a partial deletion of gene 
degP and a total deletion of ompT. This is not to say 
that the same result could not be achieved with other 
mutations of either gene resulting in each protease ei 
ther lacking significant activity or not produced by the 
gene. OmpT degP mutants can be prepared by transfer 
ring an ompT mutation into any genetic background 
containing a degP mutation using P1 transduction. Al 
ternatively, ompT degP mutants may be obtained by 
introducing a degP mutation into any genetic back 
ground containing an ompTmutation by using Pl trans 
duction or a similar technique. Any ompT ptr or degT 
ptr mutant may be prepared by standard methods of Pl 
transduction to transfer a ptr mutation into an appropri 
ate strain, usually E. coli containing a degP or ompT 
mutation. Alternatively, ompT ptr (or degP ptr) mu 
tants can be constructed by transferring an ompT (or 
degP) mutation into any genetic background deficient 
in Protease III using P1 transduction. When these mu 
tant strains are transformed with an appropriate expres 
sion vector, the proteolytically sensitive proteins ex 
pressed are recovered substantially intact, that is, with 
little or no degradation because of the deficiency in one 
or more proteases. Examples of strains which can be 
used have been deposited with ATCC with accession 
numbers 55099, 55100 and 55101. 
An important aspect of the invention is a process for 
producing proteolytically sensitive proteins by using 
the mutant microorganisms described. The mutant or 
ganism selected is transformed with an expression vec 
tor capable of expressing at least one proteolytically 
sensitive polypeptide. It will be appreciated that there 
are numerous expression vectors which may be se 
lected. For example, expression vector pFB3 is capable 
of expressing a protein A-6-lactamase fusion protein. 
Numerous other vectors are known which express 
other proteins or polypeptides, for example, proinsulin, 
phosphatase, immunoglobulin Fy fragments, epidermal 
growth factor, interleukin, interferon, somatotropin and 
5,264,365 
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insulin-like growth factors. Different proteins will be 
more or less sensitive to different proteases normally 
produced by the microorganisms. Thus, depending on 
the nature and type of polypeptide expressed, the mu 
tant organism selected for production of that polypep 
tide will contain particular protease deficiencies. The 
mutant organism containing the appropriate expression 
vector is then incubated in a suitable medium for a 
period of time allowing production of the desired pro 
tein and then the desired polypeptide product is recov 
ered. In many instances it will be desireable to use a 
multiply protease-deficient mutant organism rather than 
a single protease-deficient microorganism. 
The usefulness of protease-deficient strains for the 
expression of proteolytically sensitive polypeptides was 
tested on the fusion protein, protein A-6-lactamase. 
A-lactanase is a small monomeric protein involved in 
the hydrolysis of the B-lactam ring of many antibiotics 
such as penicillin, nitrocefin and cephaloridine while 
protein A binds with high affinity to the Ffragment of 
IgG antibodies. The fusion protein, expressed by the 
plasmid vector pFB3, is secreted into the periplasmic 
space of E. coli cells, where it assumes a fully bifunc 
tional conformation, i.e., it displays IgG binding ability 
and penicillinase enzymatic activity comparable to 
those of the authentic protein A and 6-lactamase, re 
spectively. However, although both protein A and 3 
lactanase are stable under normal conditions when 
expressed in E. coli, the fusion protein is highly suscepti 
ble to proteolytic degradation. Most of the degradation 
occurs within the g-lactamase domain of the hybrid 
protein (15). Therefore, the amount of penicillinase 
activity (e.g., g-lactamase activity against benzylpeni 
cillin) present in cells harboring the plasmid vector 
expressing the fusion protein is directly proportional to 
the amount of intact protein A-6-lactamase. This prop 
erty makes protein A-6-lactamase a suitable substrate 
for developing methods to reduce proteolysis in E. coli. 
As way of example, the expression of the fusion protein, 
protein A-6-lactamase, is markedly enhanced when 
expressed from the doubly protease-deficient mutant 
degPompT by comparison with expression either from 
ompT or degP deletion mutants. When the same expres 
sion vector is used to express the fusion protein from the 
triply deficient mutant microorganism deficient in genes 
degP, ompT and ptr the amount of fusion protein ex 
pressed is increased even further. This indicates that, in 
general, the greater the number of proteases lacking in 
the mutant organism, the more enhanced the yield of 
product recovery. 
Expression of proteolytically sensitive polypeptides 
using the mutant microorganisms will be controlled to 
some extent by the medium in which they are grown 
and some of the components added to the medium. The 
mutant microorganisms described, all of which contain 
expression vectors, grow well in complex and in mini 
mal media, for example, LB medium or M9 medium. 
Surprisingly, enhanced production of the proteins is 
observed when divalent zinc ions are added to the me 
dium. A preferable concentration is between about 0.05 
and 0.8 mM. Most preferable is a concentration of about 
0.5 mM when complex media are utilized. The pH of 
the media is preferably maintained between 5.0 and 6.5. 
In degPompT ptr mutants, expression of the protein 
A-6-lactamase fusion protein is most preferably ob 
tained in complex medium containing 0.5 mM zinc ions 











Although the mutant organisms described have been 
exemplified in singly, doubly and triply protease-defi 
cient mutant organisms, it is clearly possible to create 
mutant organisms having deficiencies in more than 
three proteases. It is well known that many gram-nega 
tive bacteria express at least seven or eight different 
proteases that degrade secreted polypeptides. Thus, 
once the appropriate genes have been cloned and the 
gene products are known, it is possible to select dele 
tions or other mutations for these singly protease-defi 
cient organisms and, by standard means, to propagate 
such mutations in other strains which themselves al 
ready contain deletions or mutations in proteolytic ac 
tivities. However, since viability and growth of the 
genetically constructed engineered organism may be of 
major concern, care must be taken to avoid the acciden 
tal deletion or mutagenesis of genes involved in cell 
viability, plasmid stability or other essential cellular 
processes and located in the vicinity of genes encoding 
proteolytic activities. 
Those of skill in the art will recognize that the meth 
ods illustrated for the construction of doubly and triply 
protease-deficient mutant microorganisms are applica 
ble to the construction of other multiply protease-defi 
cient microorganisms. Generally, a mutant protease 
gene is isolated and then recombined into the chromo 
some. Subsequently the mutated gene is transferred into 
another mutant strain, for example one that is deficient 
in one or more different proteases. The multiply pro 
tease-deficient mutant thus generated is then employed 
for the inactivation of additional proteases by repeating 
this procedure. Several proteases other than Protease 
III, OmpT and DegP are known in E. coli, for example 
Protease I, Protease Mi, Protease V or Protease VI. 
Once the gene sequence for any protease is known, it 
may be cloned and amplified, subjected to mutagenesis 
and then used to transform other cells. The procedure 
may be repeated to produce higher multiplicities of 
protease deficiencies. 
It is expected that the deactivation of a large number 
of proteolytic enzymes at some point will compromise 
the cell's viability. For this reason it is preferred that a 
set of strains deficient in different combinations of up to 
four proteases are generated. Strains containing defects 
in the subset of proteolytic enzymes that act on a partic 
ular protease sensitive polypeptide thus provide the 
highest possible production without compromising the 
cell's viability, protein synthetic capacity or genetic 
stability. Further, optimal growth conditions for each 
mutant will have to be determined as there may be some 
variations in medium, pH and trace element addition 
such as Zn2 supplementation. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the construction of the dtr32::Cat 
mutation. Only the relevant portions of the plasmid are 
shown. Restriction site abbreviations are: B, BamH I; 
Ca, Cla; H, Hind III; and S, Sal I. 
FIG. 2 is a Southern blot analysis of genomic DNA 
digested with Hind II and Cla I. Lane 1, KS272 (wild 
type); lane 2, SF 103 (ptr); lane 3, SF115 (ptr degP); lane 
4, SF120 (ptr degPompT). 
FIG. 3 shows the results of the insulin degradation 
assays. Lane 1, purified insulin control; lane 2, KS272 
(wild type); lane 3, SF103 (ptr), lane 4, SF110 (ompT 
degP); lane 5, SF120 (ptr degPompT). 
FIG. 4 shows the construction of plasmid vector 
pBF3, indicating restriction sites, localization of origins 
5,264,365 
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of replication, and the nucleotide sequence at the junc 
tion of protein A and mature g-lactamase gene. Boxes 
show the relative position of genes coding for 3-lacta 
mase (bla), protein A (spa), chloramphenicol acetyl 
transferase (cat), tetracycline resistance (tet) and lac I. 
FIG. 5 shows the results of a pulse chase analysis of 
the stability of protein A-6-lactamase in the degP strain 
KS474 (solid circles) and the ompT degP mutant SF 10 
(open circles). The fraction of protein A-g-lactamase 
(SpA-bla) remaining corresponds to the intensity of the 
band at the specified time divided by the intensity at 
time zero, as determined by scanning of the X-ray film. 
FIG. 6 shows the result of an analysis of the stability 
of protein A-3-lactamase in the wild type strain KS272 
(solid circles) and the ptr mutant SF103 (open circles). 
The fraction of protein A-f3-lactamase remaining was 
determined as in FIG.S. 
FIG. 7 shows the effect of zinc chloride addition on 





medium was supplemented with 0.2% casein amino acid 
hydrolysate, 0.2% glucose and the appropriate antibiot 
ics. W salts medium has been described (17) and consists 
of 10.5 g K2HPO4, 4.5 g KH2PO4, 0.102 g MgSO4.7- 
H2O per liter of solution containing 0.2% L-glutamine, 
0.2% glucose, and 0.2% (NH4)2SO4. Ampicillin, tetra 
cycline, kanamycin and chloramphenicol were added to 
the growth medium as required at 50 g/ml, 25 g/ml, 
50 ug/ml and 20 g/ml final concentration respec 
tively. 
Mutant E. coli deficient in one or more genes encod 
ing a protease have been deposited with the American 
Type Culture Collection (ATCC), 12301 Parklawn 
Drive, Rockville, Md. 20852 U.S.A. on Oct. 10, 1990. 
The bacteria are identified as Escherichia coli SF120 
(ATCC 55099), Escherchia coli SG103 (ATCC 55100) 
and Escherchia coli SF110 (ATCC 55101) deficient re 
spectively in ompT, degP and ptr genes (ATCC 55099), 
ptr gene (ATCC 55100), and ompT and degP genes 
degPompT mutant SF120. Relative activities represent 20 (ATCC 55101). 




















the ratio of the total penicillinase specific activity of 
cultures containing a given concentration of zinc chlo 
ride to the total penicillinase specific activity of cultures 50 
without zinc chloride. 
FIG. 8 shows the effect of pH on the expression of 
protein A-6-lactamase. Maximum total penicillinase 
activities of KS474 (degP) (solid circles) and SF110 
(ompT degP) (open circles) cells harboring the plasmid 55 
vector pFB3 are plotted versus pH. 
DETALED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
Materials and Methods 
Strains, Plasmids, Bacteriophages and Media 
The bacterial strains and plasmids used are listed in 
Table I. Bacteriophage T4 gene 2 mutant (N51am) was 
provided as a gift from E. Goldberg (Tufts Medical 65 
School, Dept. of Microbiology). Cultures were grown 
in LB medium (Difico) supplemented with 0.2% glucose 
and the appropriate concentrations of antibiotics. M9 
TABLE I 
Bacterial strains and plasmids. 
Genotype or characteristics Source or reference 
recd1903 A(lacIZYA-u169) 23 
recB2 sbcB15 his327 leu(arn) 
trpE9829 lac str32 thi 






AompT degP41 (APstl-Kan) 
AompT ptr32:0Cat 
ptr32:2Cat degP41 (APstl-Kan) 






kbp medium copy number plasmid; 29 
Cat Tet 
derivative carrying a 19 kbp 
BanH fragment mapping (thyA-argA). 
derivative carrying a 3.2 kbp Pvul 
SpA-bla fragment from pFB3; Amp. 
kbp pbR322 derivative carrying 
SpA-bla; AmpKan. 
derivative carrying an 8 kbp Sal I 
fragment encoding ptr; Amp. 




Enzymes and Chemicals 
Restriction and DNA modifying enzymes were pur 
chased from Boehringer-Mannheim, New England Bi 
olabs and Promega. All recombinant DNA procedures 
were performed according to Maniatis et al. (18) or 
Ausubel et al. (19). Oxidized insulin B-chain and penicil 
lin G were obtained from Sigma. All chemicals used 
were of biological grade. 
Southern Blots 
Southern blots were performed essentially as de 
scribed by Ausubel et aI. (19). Genomic DNA was 
isolated as described (19), separated in 0.8% agarose 
gels - and transferred overnight to nitrocellulose 
(Schleicher & Schuell BA85). DNA was crosslinked to 
nitrocellulose by baking for 2 hr at 80° C. in a vacuum 
oven. Nonradioactive digoxigenin-11-dUTP probes 
were prepared using the Genius system (Boehringer 
5,264,365 
Mannheim) according to the manufacturer's instruc 
tions. 
Pulse-Chase Experiments 
Cells were grown in labeling medium supplemented 
with 19 amino acids but no methionine (20) to mid 
exponential phase (OD=0.5 at 600 nm). 100 uCi of 
3S-Met were added to the growth medium. After two 
to five minutes, 1 ml of 0.5 mg/ml cold methionine was 
added and a zero point taken immediately. At specified 
times after initiation of the chase, 1 ml samples were 
transferred to microfuge tubes kept on ice and contain 
ing 50 ul of 34 mg/ml chloramphenicol. The cells were 
centrifuged, washed with 1 ml of 10 mM Tris HCl, pH 
8.0, resuspended in lysis buffer (10 mM Tris HCl, pH 
8.0, 1% SDS, 1 mM EDTA) and boiled for 3 minutes. 
Immunoprecipitation was performed as described (16). 
Autoradiograms were scanned with a prototype digital 
Clayton video densitometer developed at the Univer 
sity of Texas by Larry Poulson. 
Penicillinase and Insulin Degradation Assays 
3 ml samples from cultures grown as specified were 
centrifuged at 8,000 Xg for 8 min, the pellets were 
resuspended in 3 ml 50 mM potassium phosphate, pH 
6.5 and disrupted by French pressing at 20,000 psi. The 
insoluble fraction was removed by centrifugation. Peni 
cillinase activities were measured by spectrophotome 
try at 240 nm as previously described (15) using a 0.5 g/1 
penicillin G solution in 50 mM potassium phosphate, pH 
6.5 as a substrate. 
For insulin assays, cells were grown overnight in LB 
medium supplemented with 0.2% glucose and the ap 
propriate concentrations of antibiotics as required. Os 
notic fractions were collected by the method of Nossal 
and Heppel (21) and concentrated using Amicon Cen 
tricon-10 microconcentrators. 30 ug of periplasmic 
proteins were mixed with 100 mM ammonium bicar 
bonate buffer, pH 8.4, and exactly 250 ug of oxidized 
insulin B-chain was added. The final volume was 500 ul. 
Samples were incubated for 3.5 hr at 37° C. 20 ul ali 
quots (corresponding to an initial insulin concentration 
of 10 ug) were boiled in loading buffer to stop the reac 
tion and loaded onto a 22% polyacrylamide gel. 10 ug 
of purified insulin was used as a control. 
General Methods 
SDS-PAGE was performed according to Laemmli 
(22) in 22% gels. Protein concentrations were deter 
mined with the BioRad protein assay using bovine 
serum albumin as a standard. 
EXAMPLE 1. 
Construction of ompT degp Mutants 
Two mutations were combined in a single strain using 
P1 transduction to transfer chromosomal DNA from 
ompT mutant, Escherichia coli strain UT4400, into a 
degP mutant strain KS474. Strain UT4400 is a spontane 
ous mutant in which the entire ompT gene together 
with a sizable piece of adjacent DNA has been deleted 
from the chromosome. Strain KS474 contains a gene 
that confers resistance to the antibiotic kanamycin at the 
position where the degP gene is normally located. Cells 
were selected for resistance to kanamycin and to colicin 
D (resistance to this compound is encoded by one of the 













addition, the absence of OmpT was tested by examining 
the outer membrane proteins by electrophoresis (16) 
EXAMPLE 2 
Construction of ptr Mutants 
The overall strategy used to construct ptr mutants is 
shown in FIG. 1. Plasmid pCDK3 which carries a 19 
kbp insert mapping the thyA-argA region of the E. coli 
genome was digested with Sal I and BamHI. The 8 kbp 
Sal I fragment containing the ptr gene, was isolated by 
low melting point agarose. This DNA fragment was 
ligated into the unique Sal I site of plasmid pCS1 to 
yield plasmid pfB5. Plasmid pCS1 was itself generated 
by transferring the protein A-3-lactamase gene into a 
plasmid vector having a different origin of replication 
(16), pFB5 contains a unique Cla I site, located approxi 
mately 1000 bp downstream from the start codon of the 
ptr gene. A functional chloramphenicol acetyl transfer 
ase (Cat) gene was obtained in a 1.7 kbp HincII-Xmn I 
fragment from plasmid PACYC184. Plasmid pFB5 was 
linearized with Cla I, treated with Klenow to generate 
blunt ends, and ligated to the 1.7 kbp DNA fragment 
from pACYC184. Competent cells were transformed 
with the ligation mixture. Transformants were selected 
on chloramphenicol plates and tested for amplicillin 
resistance. The structure of the resulting plasmid, pFB6, 
was confirmed by restriction analysis. 
Plasmid pFB6 was digested with Sal I and the 9.7 kbp 
fragment was isolated. The chloramphenicol resistance 
insertional mutation in the ptr gene was transferred to 
the E. coli chromosome. E. coli strain D301 carries a 
tetracycline resistance insertional mutation in the recD 
gene that allows the cells to be transformed with linear 
ized DNA (23). Competent D301 cells were trans 
formed with about 1.5 ug of the 9.7 kbp linearized 
DNA and plated on chloramphenicol plates. To ensure 
that no intact pFB6 had been cotransformed, the trans 
formants were tested for ampicillin sensitivity. A chlo 
ramphenicol resistant (Cat), tetracycline resistant 
(Tet), ampicillin sensitive (Amp') colony, SF101, was 
selected. The ptr mutation was designated 
ptr32:QCat. Since SF101 is a D301 derivative, it also 
contains the tetracycline resistance insertional mutation 
in its recd gene. The ptr mutation was transferred into 
bacterial strain KS272 by generalized P1 transduction. 
Transductants containing the ptr32:2Cat mutation 
were isolated on the basis of chloramphenicol resis 
tance. These colonies were further selected for tetracy 
cline sensitivity to ensure that they did not contain the 
recD mutation present in D301. This process yielded an 
E. coli strain carrying a chloramphenicol resistance 
insertional mutation in the ptr gene as well as a func 
tional recD gene, i.e. having an intact exonuclease V 
activity. The selected strain SF103 has been deposited 
with ATCC, Accession number 55100. 
The correct insertion of the chloramphenicol car 
tridge was confirmed by Southern blotting (FIG. 2). A 
Hinc II-Xmn I chloramphenicol probe derived from 
plasmid pACYC184 and labeled with digoxigenin-11 
dUTP hybridized with HincII--Cla I digested genomic 
DNA from SF103 (lane 2) but did not hybridize with 
DNA from the parental strain KS272. 
Because Protease III is the only cell envelope prote 
ase which has been reported to rapidly degrade insulin, 
the absence of Protease III proteolytic activity in the 
ptr32:0Cat mutant SF103 was demonstrated as fol 
lows. Strains KS272 and SF103 were grown in LB 
5,264,365 
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medium supplemented with glucose and the appropriate 
antibiotics for 24 hours. The periplasmic fraction of the 
cells was collected by the method of Nossal and Heppel 
(21) and concentrated by ultrafiltration. Periplasmic 
proteins were incubated with oxidized insulin B-chain 
and resolved by SDS-PAGE as described in Materials 
and Methods. FIG. 3 shows that no appreciable degra 
dation was observed with SF103 (lane 3). In contrast, 
no intact insulin could be detected after incubation with 
the osmotic shock fractions of the isogenic strains 
KS272 (lane 2). Therefore, the ptr32::S)Cat mutant 
SF103 does not possess the insulin degrading activity 
typical of strains containing an intact Protease III activ 
ity. 
Finally, the presence of an intact exonuclease V ac 
tivity in SF103 was demonstrated in the following man 
ner. E. coli cells containing a defective exonuclease V 
enzyme (e.g., a mutation in one or more of the recs, 
recCand recd genes) are fully permissive for bacterio 
phage T4 gene 2 mutants (T42-). However, T42- is 
unable to infect cells containing an intact exonuclease V 
activity. Strains JC7729, KS272 and SF103 were in 
fected at different multiplicities of infection with T4 
2 (amN51) as described (24). Although T42- formed 
numerous plaques on the recB strain JC7729 (the titer of 
the phage was about 3X 109 PFU/ml on JC7729), none 
were obtained on KS272 or SF103, indicating the pres 
ence of a fully functional exonuclease V in these strains. 
Furthermore, streaks of SF103 cells exposed to 1.1 mW 
of UV radiation per cm2 for up to 100 seconds did not 
display the reduced viability typically observed in recB 
recC recD mutants. The ptr mutant SF103 grew to an 
optical density at 600 nm of about 1.8 in a variety of 
media (e.g., LB, M9, W salts). 
EXAMPLE 3 
Construction of ptr degP Mutants 
Pl generalized transduction was used to transfer the 
ptr32:QCat mutation from SF101 to a degP mutant 
KS474. Transductants were selected for chlorampheni 
col resistance and tetracycline sensitivity to confirm the 
presence of the ptr mutation and the absence of the 
recD mutation respectively. The resulting colonies 
were further tested for kanamycin resistance, indicating 
the presence of the degP mutation. 
The resulting double protease-deficient strain, SF115, 
was tested for (i) proper insertion of the chlorampheni 
col resistance cartridge (FIG. 2, lane 3), (ii) absence of 
proteolytic activity against insulin, and (iii) presence of 
an intact exonuclease V activity, with a series of tests as 
described in Example 2. 
EXAMPLE 4 
Construction of ptrompT Mutants 
Mutants in both ptr and ompT were constructed in a 









the ptr degP double mutant SF115, described in Exam 
ple 3, except that P1 generalized transduction was used 
to transfer the ptr32:0Cat mutation from SF101 to 
SF100. The latter strain contains a deletion in the chro 
mosome which includes the ompT gene (16). Transduc 
tants were selected for chloramphenicol resistance and 
tetracycline sensitivity to confirm the presence of the 
ptr mutation and the absence of the recD mutation, 
respectively. 
The resulting double protease-deficient strain SF112, 
was tested for (i) proper insertion of the chlorampheni 
col resistance cartridge, (ii) absence of proteolytic ac 
tivity against insulin, and (iii) presence of an intact exo 
nuclease V activity, as described in Example 2. 
EXAMPLE 5 
Construction of ptr degPompT Mutants 
Generalized P1 transduction was used to transfer the 
ptr32:0Cat mutation from strain SF101 obtained as 
described in Example 2 into ompT degP mutants as 
obtained in Example 1. Transductants were selected for 
chloramphenicol resistance and tetracycline sensitivity 
to confirm the presence of the ptr mutation and the 
absence of the recD mutation, respectively. The result 
ing colonies were further tested for kanamycin resis 
tance, indicating the presence of the degP mutation. 
The selected triply protease-deficient mutant strain was 
designated SF120 and is on deposit with ATCC, Acces 
sion number 55099. 
Strain SF120 was tested for (i) proper insertion of the 
chloramphenicol resistance cartridge (FIG. 2, lane 4), 
(ii) absence of proteolytic activity against insulin (FIG. 
3, lane 5), and (iii) presence of an intact exonuclease V 
activity, with a series of tests as described in Example 2. 
EXAMPLE 6 
Expression of Protein A-6-Lactamase from 
Protease-Deficient Mutants 
Plasmid pFB3 encodes a hybrid protein constructed 
by in-frame fusion of the genes coding for Staphylococ 
cus aureus protein A and the E. coli enzyme TEM (3-lac 
tamase (FIG. 4). S-lactamase is a small, monomeric 
enzyme involved in the hydrolysis of the 6-lactam ring 
of many antibiotics such as penicillin, nitrocefin, and 
cephaloridine. A-lactamase activity against the substrate 
benzylpenicillin was determined using the spectropho 
tometric methods described in Materials and Methods. 
The protease-deficient mutants described in Exam 
0 ples 1 to 6 were shown to augment the expression of 
55 
protein A-fé-lactamase as follows: Strains KS272, 
KS474, SF103, SF 10, SF115 and SF 120 were trans 
formed with the plasmid vector pFB3. Cultures were 
grown for 24 hours in LB medium and the total penicil 
linase activity was assayed as described in Materials and 
Methods. Penicillinase specific activities of these strains 
are shown in Table II. 
TABLE I 
Influence of different protease-deficient mutant strains on the expression of 
protein A-6-lactanase from the plasmid vector prE3. 
Total penicillinase 
Strain Strain Growth specific activity 
(plasmid) Characteristics medium (U/mg) - SD % increase 
KS272(pFB3) ompt degP+ ptr LB 15.2 - 2.9 
KS474(pFB3) ompT degP ptr! LB 47.9 8.3 25 
SF100(pFB3) ompT degP+ ptrt LB 28.2 7. 85 
SF103(pFB3) ompT degP+ ptr LB 32.6 12.5 15 
SF110(pFB3) ompT degP ptr. LB 87.9 17.2 478 





Influence of different protease-deficient mutant strains on the expression of 
protein A-6-lactamase from the plasmid vector prB3. 
Total penicillinase 
Strain Strain Growth specific activity 
(plasmid) Characteristics medium (U/ng) - SD % increase 
SF120(pFB3) ompT degP ptr LB 86.9 10. 427 
Table II indicates that a single mutation in the ptr 
gene (strain SF103 described in Example 2) increased 
the expression of protein A-3-lactamase by about 2-fold 
10 mutation in the degP, ompT background resulted in a reproducible 33% increase in protein A-3-lactamase 
expression, as shown in Table III. 
TABLE II 
Total penicillinase activities of double and triple protease-deficient mutants 
transformed with the plasmid vector prB3. 
Total penicillinase 
Strain Strain Growth specific activity 
(plasmid) Characteristics medium (U/mg) - SD % increase 
SF110(pFB3) ompT degP ptr. M9 4.8 0.4 - 
SF120(pFB3) ompT degP ptr M9 6.4 0.8 33 
compared to the parental strain KS272. This improve 
ment is comparable to that observed with the single 
ompT mutant SF100 (lane 3). An approximate 3-fold 
increase in expression is obtained with the single degP 
mutant KS474. Use of the double mutants SF110 (ompT 
degP) and SF115 (ptr degP) described in Examples 1 
and 3, respectively, increases the expression of protein 
A-g-lactamase by more than 5-fold relative to the pa 
25 
The effect of zinc chloride addition to protease-defi 
cient cells grown in minimal medium W salts is shown 
in Table IV. Protein A-g-lactamase expression from 
SF110 harboring plasmid vector pFB3 was increased by 
46%. when 0.1 mM ZnCl2was added to the medium. 
The effect on SF120 cells harboring pFB3 was an in 
crease of 53% when grown under the same conditions. 
TABLE IV 
Effect of zinc chloride addition to the growth medium of cells deficient in multiple 
proteases on the expression of protein A-6-lactamase from the plasmid vector pFB3. 
Relative penicillinase 
Strain Strain Growth specific activity 
(plasmid) characteristics medium (% t SD) 
SF110(pFB3) ompT degP ptrt W 100 
SF110(pFB3) ompT degP ptrt W + 0.1 mM ZnCl2 146 6 
SF120(pFB3) ompT degP ptr W 100 
SF120(pFB3) ompT deg ptr W + 0.1 mM ZnCl2 153 - 9 
rental strain KS272. The triple mutant SF120 (ptr degP 
ompT) described in Example 5, also provided a 5 to 
6-fold increase in protein A-6-lactamase expression. 
Enhanced expression levels of protein A-6-lactamase 
in the ompT degP double mutant SF110 were con 
firmed by radioactive pulse-chase experiments as de 
scribed in Materials and Methods. FIG. 5 shows that 
the half-life of the fusion protein was approximately 30 
min in the degP single mutant strain KS474, but was 
increased to about 100 minutes in the ompT degP dou 
ble mutant strain SF110. Essentially no degradation of 
the fusion protein was evident in the double mutant for 
the first hour following the initiation of the chase, dem 
onstrating that E. coli strains deficient in multiple pro 
teases also provide enhanced levels of expression of 
protein A-6-lactamase in exponentially growing cells. 
Similarly, no degradation of protein A-3-lactamase 
was observed in the ptr mutant SF103 for the first 30 
minutes following the initiation of the chase (FIG. 6). 
EXAMPLE 7 
Effect of Medium, pH and Metal Ions on Protein 
A-g-Lactamase Expression in Protease-Deficient 
Mutants 
Strains SF110 (ompT degP) and SF120 (ptr degP 
ompT) were transformed with plasmid vector plb3 
and grown in M9 medium. Total specific penicillinase 






Triply protease-deficient SF120 cells transformed 
with the plasmid expression vector pFB3 were grown 
in complex medium LB to which up to 1 mM zinc chlo 
ride was added. As shown in FIG. 7, maximum expres 
sion of protein A-3-lactamase was observed when ap 
proximately 0.5 mM Zn2 was added to the medium. 
The effect of pH on protein A-3-lactamase expres 
sion in cells transformed with plasmid vector p3F3 was 
determined. Fermentations were carried out in Bioflo 
III fermenters with a working volume of 2 liters and 
followed for 24 hrs. The pH was maintained at a con 
stant value by automatic addition of 1 M HCl or 1 M 
NaOH to growth medium LB supplemented with 0.2% 
glucose and 50 g/ml ampicillin. Fermenters were in 
oculated with 25 or 50 ml of transformed E. coli strain 
KS474, deficient in degP, or SF 10, deficient in ompT 
and degP. FIG. 8 shows that maximum expression of 
the fusion protein was obtained when the pH was main 
tained between 5.5 and 6.0. 
PROPHETIC EXAMPLE 8 
The present example outlines the procedure contem 
plated by the Applicants to be useful for the successful 




Construction of ptrompT degP Protease VI Mutants 
Construction of mutant organisms will involve the 
following steps: (1) cloning and amplification of a gene 
or part of a gene of a protease; (2) mutagenesis of the 5 
isolated gene sequence to allow easy selection of the 
mutants; (3) recombination of the mutated gene se 
quence into the chromosome; and (4) transfer of the 
mutation into a strain deficient in three proteases. 
Protease VI is isolated and purified from Escherichia O 
coli using well known techniques (25-27). The amino 
terminal sequence of the purified protein is determined 
by gas phase sequencing. Degenerate oligonucleotide 
primers corresponding to the sequence of the first six or 
Seven N-terminal amino acids are prepared by auto 
mated solid phase synthesis (19). The primers are de 
signed so that a suitable restriction site is generated 
upon annealing to a plasmid library of E. coli genomic 
DNA. Amplification is carried out by polymerase chain 
reaction (PCR) using an additional primer which corre 
sponds to a plasmid sequence The amplified DNA is 
isolated and subcloned within a suitable vector contain 
ing appropriate restriction sites. The gene or part of the 
gene thus amplified is then used to screen an ordered 25 
plasmid E. coli library so that the gene is identified in the 
physical map of the genome, subsequently allowing the 
entire gene to be cloned. Once the protease gene has 
been cloned on a plasmid, mutations are generated ei 
ther in vitro as described in Example 2 or in vivo by 30 
employing transposon mutagenesis with Tn 10 which is 
a transposon carrying tetracycline resistance. A muta 
tion resulting in deletion of a substantial fraction of the 
gene's DNA and linked to the antibiotic resistance gene 
is then isolated. The mutation is then transferred into 35 
the triple mutant strain SF120 to generate a quadruple 
mutant strain exhibiting substantial reduction in four 
protease activities. Strains in which the transposon has 
been excised are isolated by screening for cells that have 
lost the selectable marker. These cells will not exhibit 40 
tetracycline resistance but will be defective in Protease 
VI as well as OmpT, DegP and Protease III. 
REFERENCES 
The references listed below are incorporated herein 
by reference to the extent they supplement, explain, 
provide a background for or teach methodology, tech 
niques and/or compositions employed therein. 
1. Georgiou, G., AIChE. J. 34, 1233-1248 (1988). 
2. Huse, W. D., Lakshmi, S., Iverson, S.A., Kang, A. 
S., Alting-Mees, M., Burton, D. R., Benkovic, S. J. 
and Lerner, R. A., Science 246, 1275-1280 (1989). 
3. Baneyx, F. and Georgiou, G., in Stability of Protein 
Pharmaceuticals: Chemical and Physical Pathways of 55 
Protein Degradation in press. 
4. Goldberg, A. L. and St. John, A. C., Ann. Rev. Bio 
chem. 45, 747-803 (1976). 
5. Hershko, A. and Ciechanover, A., Ann. Rev. Bio 
chem. 51, 335-364 (1982). 60 
6. Lazdunski, A. M., FEMS Microbiol. Rev. 63, 
265-276 (1989). 
7. Miller, C. G. in Escherichia coli and Salmonella typhi 
murium. Cellular and Molecular Biology, Vol. 1, F. 
C. Neidhardt, Ed., American Society for Microbiol- 65 
ogy, Washington, DC, pp 680-691, 1987. 
8. Field, H., Rees, A. R., Yarranton, G. T., WO 





9. Beckwith, J. R. and Strauch, K. L., WO 88/05821, 
Aug. 11, 1988. 
10. Chaudhury, A. and Smith G. R., J. Bacteriol. 160, 
788-791 (1984). 
1. Elish, M. E., Pierce, J. R. and Earhart, C. F., J. Gen. 
Microbiol. 134, 1355–1364 (1988). 
12. McIntosh, M.A., Chenault, S. S. and Earhart, C. F., 
J. Bacteriol. 137, 653-657 (1979). 
13. Cheng, Y. S. E. and Zipser, D., J. Biol. Chem. 254, 
4698-4706 (1979). 
14. Strauch, K. and Beckwith, J. Proc. Natl. Acad. Sci. 
U.S.A. 85, 1576-1580 (1988). 
15. Baneyx, F. and Georgiou, G., Enzyme Microb. 
Technol. 11, 559-567 (1989). 
16. Baneyx, F. and Georgiou, G., J. Bacteriol. 172, 
491-494 (1990). 
17. Smith, G. R., Halpern, Y. S. and Magasanik, J. Biol. 
Chem. 246, 3320-3329 (1971). 
18. Maniatis, T., Fritsch, E. F. and Sambrook, J. in 
Molecular Cloning: A Laboratory Manual, Cold 
Spring Harbor, NY, Cold Spring Harbor Laboratory 
Press, 1982. 
19. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, 
D. D., Seidman, J. G., Smith, J. A. and Struhl, K. in 
Current Protocols in Molecular Biology, John Wiley 
& Sons, New York, NY (1987). 
20. Georgiou, G., Shuler, M. L. and Wilson, D. B., 
Biotechnol. Bioeng. 32, 741-748 (1988). 
21. Nossal, N. G. and Heppel, L. A., J. Biol. Chem. 241, . 
3055-3062 (1966). 
22. Laemmli, U. K., Nature (London) 227, 680-685 
(1970). 
23. Russell, C. B., Thaler, D. S. and Dahlquist, F. W., J. 
Bacteriol. 171,2609-2613 (1989). 
24. Weichenhan, D. and Wachkernagel, W., Molecular 
Microbiology 3, 1777-1784 (1989). 
25. Swamy, S. K. H. and Goldberg, A. L., J. Bacteriol. 
149, 1027-1033 (1982). 
26. Palmer, S. M. and St. John, A. C., J. Bacteriol. 169, 
1474-1479 (1987). 
27. PaCaud, M., J. Biol. Chem. 257, 4333-4339 (1982). 
28. Strauch, K. L., Johnson, K. and Beckwith, J., J. 
Bacteriol. 171,2689-2696 (1989). 
29. Chang, A. C. Y. and Cohen, S. N., J. Bacteriol. 134, 
1141-1156 (1978). 
30. Dykstra, C. C., Prasher, D. and Kushner, S. R., J. 
Bacteriol. 157, 21-27 (1984). 
What is claimed is: 
1. A genetically engineered Escherichia coli or Salmo 
nella typhimurium bacterium deficient in chromosomal 
genes ptr, ompT and degP encoding proteases Protease 
III, OmpT, and DegP, respectively. 
2. A genetically engineered Escherichia coli or Salmo 
nella typhimurium bacterium deficient in chromosomal 
genes degP and ompT encoding DegP and OmpT, 
respectively. 
3. A genetically engineered Escherichia coli or Salmo 
nella typhimurium bacterium deficient in chromosomal 
genes degP and ptr encoding proteases DegP and Pro 
tease III respectively. 
4. A genetically engineered Escherichia coli or Salmo 
nella typhimurium bacterium deficient in chromosomal 
genes ompT and ptr encoding proteases OmpT and 
Protease III respectively. 
5. A mutant E. coli strain SF 120 having ATCC acces 
sion number 55099 deposited Oct. 10, 1990. 
6. A mutant E. coli strain SF 110having ATCC acces 
sion number 55101 deposited Oct. 10, 1990. 
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